LISATA THERAPEUTICS INC
LSTANASDAQTrading Snapshot
- Day Range
- $1.45 – $1.48
- 52-Week Range
- $0.99 – $5.07
- Volume
- $1.68B
- Avg Volume
- $1.42B
- Shares Outstanding
- 9.1M
- Next Earnings
- Nov 30, 2026
Fundamentals Snapshot
- Annual Revenue
- $170,000
- Last Q Revenue
- $43,366
- P/E Ratio
- —
- P/S Ratio
- 83.7x
- EPS (TTM)
- $-1.14
- Dividend Yield
- —
- Dilution (1yr)
- +4.3%
Why Investors Own LSTA
- ✓High-growth profile — revenue up +29.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 45% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
LISATA THERAPEUTICS INC
LSTA
StockOtter · stockotter.spaceAbout LISATA THERAPEUTICS INC
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Lisata subsidiary Marea Therapeutics gets late-breaking slot at AHA Scientific Sessions
Marea Therapeutics, a subsidiary of Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), said data from the Phase 2b TYDAL study of its lead candidate MAR001 will be presented in a late-breaking science session at the America
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
SOUTH SAN FRANCISCO and LIBERTY CORNER, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage biotechnology com
Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy
Lisata Therapeutics, Inc. (NASDAQ:LSTA) on Thursday announced it has acquired clinical-stage biotechnology company Marea Therapeutics, Inc. alongside an oversubscribed $225 million private placement financing.
Lisata Therapeutics acquires Marea Therapeutics, secures $225 million private placement
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has acquired Marea Therapeutics, a clinical-stage biotech developing next-generation medicines for cardioendocrine diseases. The companies also entered a private placement
Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseases Marea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG) c
Anthropic is compounding, OpenAI is flatlining, and the betting markets have noticed
Two of the biggest listings in market history are queued up for the back end of this year, and punters are already pricing the run-in. Polymarket has opened...